{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["McDermott JH"],"funding":["NCATS NIH HHS","Rho Chi Society","NIDCD NIH HHS","American Foundation for Pharmaceutical Education","National Institute on Deafness and Other Communication Disorders","NHGRI NIH HHS","National Institute for Health Research (NIHR)","NIHR BRC","National Institutes of Health","PharmGKB"],"pagination":["366-372"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8613315"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["111(2)"],"pubmed_abstract":["Aminoglycosides are widely used antibiotics with notable side effects, such as nephrotoxicity, vestibulotoxicity, and sensorineural hearing loss (cochleotoxicity). MT-RNR1 is a gene that encodes the 12s rRNA subunit and is the mitochondrial homologue of the prokaryotic 16s rRNA. Some MT-RNR1 variants (i.e., m.1095T>C; m.1494C>T; m.1555A>G) more closely resemble the bacterial 16s rRNA subunit and result in increased risk of aminoglycoside-induced hearing loss. Use of aminoglycosides should be avoided in individuals with an MT-RNR1 variant associated with an increased risk of aminoglycoside-induced hearing loss unless the high risk of permanent hearing loss is outweighed by the severity of infection and safe or effective alternative therapies are not available. We summarize evidence from the"],"journal":["Clinical pharmacology and therapeutics"],"pubmed_title":["Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on MT-RNR1 Genotype."],"pmcid":["PMC8613315"],"funding_grant_id":["R01 DC017955","R01 DC002842","U24 HG010135","R01 DC016680","R56 DC004555","U24 HG010615","R01 DC004555","TL1TR001858","DC004555","IS-BRC-1215-20007","R01 DC012049","IS‐BRC‐1215‐20007","DC016680","TL1 TR001858"],"pubmed_authors":["Huddart R","McDermott JH","Whirl-Carrillo M","Klein TE","Steyger PS","Rodriguez-Antona C","Wolf J","Newman WG","Smith RJH","Hoshitsuki K","Caudle KE","Cody N"],"additional_accession":[]},"is_claimable":false,"name":"Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on MT-RNR1 Genotype.","description":"Aminoglycosides are widely used antibiotics with notable side effects, such as nephrotoxicity, vestibulotoxicity, and sensorineural hearing loss (cochleotoxicity). MT-RNR1 is a gene that encodes the 12s rRNA subunit and is the mitochondrial homologue of the prokaryotic 16s rRNA. Some MT-RNR1 variants (i.e., m.1095T>C; m.1494C>T; m.1555A>G) more closely resemble the bacterial 16s rRNA subunit and result in increased risk of aminoglycoside-induced hearing loss. Use of aminoglycosides should be avoided in individuals with an MT-RNR1 variant associated with an increased risk of aminoglycoside-induced hearing loss unless the high risk of permanent hearing loss is outweighed by the severity of infection and safe or effective alternative therapies are not available. We summarize evidence from the","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-04-19T17:56:20.836Z","creation":"2025-04-19T17:56:20.836Z"},"accession":"S-EPMC8613315","cross_references":{"pubmed":["34032273"],"doi":["10.1002/cpt.2309"]}}